The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors.
Rachel E. Sanborn
No relevant relationships to disclose
William Howard Sharfman
Consultant or Advisory Role - Merck
Neil Howard Segal
No relevant relationships to disclose
F. Stephen Hodi
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Walter John Urba
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Bernard A. Fox
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb
Suzanne Louise Topalian
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb
Other Remuneration - Amplimmune (I); Bristol-Myers Squibb (I)
Drew M. Pardoll
Consultant or Advisory Role - Aduro Biotech (U); Amplimmune (U); ImmuneXcite (U)
Kelly L. Covello
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Dan McDonald
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Su Young Kim
Employment or Leadership Position - Bristol-Myers Squibb
Ashok Kumar Gupta
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Jon M. Wigginton
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Thomas Gajewski
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb